Nucana Plc (NCNA) Gets a Buy Rating from H.C. Wainwright

By Carrie Williams

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Nucana Plc (NCNAResearch Report), with a price target of $20.00. The company’s shares closed last Monday at $7.50.

According to TipRanks.com, Selvaraju ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -17.5% and a 25.3% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Taro Pharmaceutical Industries Ltd., Biospecifics Technologies Corp, and Turning Point Therapeutics Inc.

Nucana Plc has an analyst consensus of Strong Buy, with a price target consensus of $23.33, a 238.1% upside from current levels. In a report issued on October 25, Cowen & Co. also maintained a Buy rating on the stock.

See today’s analyst top recommended stocks >>

Based on Nucana Plc’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $5.75 million. In comparison, last year the company had a GAAP net loss of $3.28 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying our phosphoramidate chemistry technology to transform some of the most widely prescribed chemotherapy agents into more effective and safer medicines.